FDA Approved: HICON — Supplemental Application (Jubilant DraxImage Inc., dba Jubilant Radiopharma)

View source ↗

Summary

FDA approved a supplemental application for HICON (Sodium Iodide I-131) from Jubilant Radiopharma, resulting in updated labeling for this radiopharmaceutical.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer
• Hyperthyroidism
• Toxic Nodular Goiter

Drugs mentioned

• HICON (Sodium Iodide I-131)

Snippet

SUPPL AP for HICON (SODIUM IODIDE I 131)